Donovan Joanne M.
SEC CIK 1644087 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| EWTX | Edgewise Therapeutics, Inc. | CMO | 8,625 | — | $5.74M | 20 | 2023-05-01 | 2026-08-12 |
Most active insiders at EWTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Russell Alan J | CSO, Dir | — | $10.25M |
| 2 | Donovan Joanne M. | CMO | — | $4.62M |
| 3 | Edris Badreddin | Dir | — | $3.40M |
| 4 | KOCH KEVIN | Pres, CEO, Dir | — | $785.0K |
| 5 | Derakhshan Behrad | Chief Business Off | — | $223.4K |
| 6 | MOORE JOHN R | GC | — | $219.8K |
| 7 | Fox Jonathan C | Dir | $199.4K | — |
Transactions 20
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-08-14 16:54 | 2026-08-12 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | M - OptEx | $0.00 | +12.8K | 18.1K | +244% | $0 |
| DM | 2026-08-14 16:54 | 2026-08-12+ | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | S - Sale+OE | $43.71 | -9,441 | 8,625 | -52% | -$412.7K |
| DM | 2026-05-05 13:15 | 2026-05-04+ | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | S - Sale+OE | $37.88 | -55.2K | 4,367 | -93% | -$2.09M |
| D | 2026-05-05 13:15 | 2026-05-05 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | M - OptEx | $7.08 | +50.0K | 54.4K | +1,145% | +$354.0K |
| DT | 2026-04-02 13:01 | 2026-04-01 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | M - OptEx | $7.08 | +28.7K | 38.3K | +299% | +$202.9K |
| DT | 2026-04-02 13:01 | 2026-04-01 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | S - Sale+OE | $32.31 | -28.7K | 9,597 | -75% | -$926.1K |
| DT | 2026-03-31 | 2026-03-31 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | S - Sale+OE | $32.12 | -21.3K | 9,597 | -69% | -$685.4K |
| DT | 2026-03-31 | 2026-03-31 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | M - OptEx | $7.08 | +21.3K | 30.9K | +222% | +$151.1K |
| MT | 2026-03-30 | 2026-03-27 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | S - Sale | $30.98 | -16.4K | 9,597 | -63% | -$506.8K |
| D | 2025-08-14 | 2025-08-12 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | S - Sale+OE | $13.39 | -2,862 | 25.4K | -10% | -$38.3K |
| D | 2025-08-14 | 2025-08-12 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | M - OptEx | $0.00 | +5,781 | 28.2K | +26% | $0 |
| D | 2025-05-07 | 2025-05-01 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | M - OptEx | $0.00 | +10.4K | 26.8K | +64% | $0 |
| D | 2025-05-07 | 2025-05-02 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | S - Sale+OE | $16.45 | -5,187 | 21.6K | -19% | -$85.3K |
| DT | 2025-01-30 | 2025-01-28 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | M - OptEx | $7.08 | +25.0K | 41.4K | +153% | +$177.0K |
| DT | 2025-01-30 | 2025-01-28 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | S - Sale+OE | $27.63 | -25.0K | 16.4K | -60% | -$690.8K |
| 2024-09-24 | 2024-09-20 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | S - Sale | $28.29 | -7,162 | 14.5K | -33% | -$202.6K | |
| D | 2024-05-03 | 2024-05-02 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | S - Sale+OE | $18.91 | -3,682 | 19.9K | -16% | -$69.6K |
| D | 2024-05-03 | 2024-05-01 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | M - OptEx | $0.00 | +10.4K | 23.6K | +79% | $0 |
| D | 2023-05-03 | 2023-05-01 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | M - OptEx | $0.00 | +10.4K | 13.2K | +372% | $0 |
| D | 2023-05-03 | 2023-05-02 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | S - Sale+OE | $8.90 | -3,254 | 9,960 | -25% | -$29.0K |
Purchase Sale Sale after option exercise All abbreviations